Physician profile
Heather E Bastel
NPI 1396712287
$2,482.07
in general payments reported to CMS, 2019-2025
24 companies · $371 in 2025
The $371 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $358 · 2022: $268 · 2023: $953 · 2024: $533 · 2025: $371.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,856.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,856.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $485.96 | 2022-2025 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $393.36 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Otsuka America Pharmaceutical, INC. | $379.24 | 2022-2025 | Rexulti |
| Abbvie INC. | $277.66 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $190.74 | 2021-2024 | Jardiance |
| Glaxosmithkline, LLC. | $175.35 | 2021-2025 | Trelegy Ellipta |
| Bayer Healthcare Pharmaceuticals INC. | $151.26 | 2023-2024 | |
| E.R. Squibb & Sons, L.L.C. | $49.56 | 2022-2024 | Eliquis |
| Biohaven Pharmaceuticals, INC. | $44.76 | 2021 | |
| Lilly USA, LLC | $44.21 | 2021-2023 | Mounjaro |
| Idorsia Pharmaceuticals US INC | $42.07 | 2023 | Quviviq |
| Axsome Therapeutics, INC. | $38.17 | 2025 | Auvelity |
| Biohaven Pharmaceutical Holding Company LTD. | $31.06 | 2022 | |
| Amgen INC. | $30.73 | 2024-2025 | Repatha, Otezla |
| Genentech USA, INC. | $28.76 | 2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $24.11 | 2021 | |
| Hologic Sales and Service, LLC | $15.99 | 2024 | Aptima, Thinprep 2000 Processor |
| Xeris Pharmaceuticals, INC. | $15.80 | 2023 | Gvoke Hypopen |
| Pfizer INC. | $15.21 | 2023 | |
| Teva Pharmaceuticals USA, INC. | $15.01 | 2022 | |
| Merck Sharp & Dohme LLC | $14.51 | 2021 | |
| Esperion Therapeutics, INC. | $12.28 | 2021 | |
| Phathom Pharmaceuticals, INC. | $3.19 | 2025 | Voquezna |
| Corium, LLC | $3.08 | 2023 | Adlarity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Bastel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.